Dosing Frequency of Unfractionated Heparin Thromboprophylaxis A Meta-analysis

被引:31
作者
Phung, Olivia J. [1 ]
Kahn, Susan R. [2 ]
Cook, Deborah J. [3 ,4 ,5 ]
Murad, Mohammad Hassan [6 ,7 ]
机构
[1] Western Univ Hlth Sci, Coll Pharm, Pomona, CA 91766 USA
[2] McGill Univ, Dept Med, Montreal, PQ, Canada
[3] McMaster Univ, Dept Med, Hamilton, ON, Canada
[4] McMaster Univ, Dept Clin Epidemiol, Hamilton, ON L8S 4L8, Canada
[5] McMaster Univ, Dept Biostat, Hamilton, ON, Canada
[6] Mayo Clin, Div Prevent Med, Rochester, MN USA
[7] Mayo Clin, Knowledge & Evaluat Res Unit, Rochester, MN USA
关键词
MOLECULAR-WEIGHT HEPARIN; DEEP-VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; MEDICAL PATIENTS; ACUTELY ILL; NONSURGICAL PATIENTS; CONTROLLED-TRIAL; PREVENTION; PROPHYLAXIS; NADROPARIN;
D O I
10.1378/chest.10-3084
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Background: In medical patients, it is unclear whether thromboprophylaxis with low-dose unfractionated heparin (UFH) should be administered bid or tid. Methods: This study was a mixed-treatment comparison meta-analysis of randomized control trials that enrolled hospitalized nonsurgical patients at risk for VTE and compared UFH bid, UFH tid, or low-molecular-weight heparin (LMWH) to one another or to an inactive control subject. DVT, pulmonary embolism (PE), major bleeding, and death were measured. A Bayesian framework using a random-effects model was applied. Results: Sixteen trials with moderate methodologic quality enrolling 27,667 patients contributed to this analysis. The relative risk and 95% credible intervals comparing UFH lid to UFH bid for DVT, PE, death, and major bleeding were 1.56 (0.64-4.33), 1.67 (0.49-208.09), 1.17 (0.72-1.95), and 0.89 (0.08-7.05), respectively. When compared with either dose of UFH, the use of LMWH has an effect similar to UFH on all four outcomes. Conclusions: Moderate-quality evidence suggests that subcutaneous UFH bid and UFH lid do not differ in effect on DVT, PE, major bleeding, and mortality. Either of the two dosing regimens of UFH or LMWH appears to be a reasonable strategy for thromboprophylaxis in medical patients. A future randomized trial comparing the two doses of UFH is very unlikely, considering the very large sample size that would be required to demonstrate a significant difference, which, if it exists, is undoubtedly small. CHEST 2011; 140(2):374-381
引用
收藏
页码:374 / 381
页数:8
相关论文
共 25 条
  • [11] SMALL SUBCUTANEOUS DOSES OF HEPARIN IN PREVENTION OF VENOUS THROMBOSIS
    GALLUS, AS
    HIRSH, J
    TUTTLE, RJ
    TREBILCOCK, R
    OBRIEN, SE
    CARROLL, JJ
    MINDEN, JH
    HUDECKI, SM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1973, 288 (11) : 545 - 551
  • [12] Gardlund B, 1996, LANCET, V347, P1357
  • [13] Prevention of venous thromboembolism
    Geerts, William H.
    Bergqvist, David
    Pineo, Graham F.
    Heit, John A.
    Samama, Charles M.
    Lassen, Michael R.
    Colwell, Clifford W.
    [J]. CHEST, 2008, 133 (06) : 381S - 453S
  • [14] PREVALENCE AND PREVENTION OF DEEP VENOUS THROMBOSIS OF THE LOWER-EXTREMITIES IN HIGH-RISK PULMONARY PATIENTS
    IBARRAPEREZ, C
    LAUCORTES, E
    COLMENEROZUBIATE, S
    AREVILACEBALLOS, N
    FONG, JH
    SANCHEZMARTINEZ, R
    DOMINGUEZ, MV
    ELIZALDEGONZALEZ, J
    [J]. ANGIOLOGY, 1988, 39 (06) : 505 - 513
  • [15] Twice vs three times daily heparin dosing for thromboembolism prophylaxis in the general medical population - A metaanalysis
    King, Christopher S.
    Holley, Aaron B.
    Jackson, Jeffrey L.
    Shorr, Andrew F.
    Moores, Lisa K.
    [J]. CHEST, 2007, 131 (02) : 507 - 516
  • [16] Acute ischemic heart disease - Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease
    Kleber, FX
    Witt, C
    Vogel, G
    Koppenhagen, K
    Schomaker, U
    Flosbach, CW
    [J]. AMERICAN HEART JOURNAL, 2003, 145 (04) : 614 - 621
  • [17] Lechler E, 1996, HAEMOSTASIS, V26, P49
  • [18] The prophylaxi's of medical patients for thromboembolism pilot study
    Lederle, FA
    Sacks, JM
    Fiore, L
    Landefeld, CS
    Steinberg, N
    Peters, RW
    Eid, AA
    Sebastian, J
    Stasek, JE
    Fye, CL
    [J]. AMERICAN JOURNAL OF MEDICINE, 2006, 119 (01) : 54 - 59
  • [19] Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients
    Leizorovicz, A
    Cohen, AT
    Turpie, AGG
    Olsson, CG
    Vaitkus, PT
    Goldhaber, SZ
    [J]. CIRCULATION, 2004, 110 (07) : 874 - 879
  • [20] Combination of direct and indirect evidence in mixed treatment comparisons
    Lu, G
    Ades, AE
    [J]. STATISTICS IN MEDICINE, 2004, 23 (20) : 3105 - 3124